People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| 1859, Inc. | — | Biotechnology | Series B | $52.2M | $878.6M | 2019 |
| Alida Biosciences Inc. | — | Biotechnology | Series A | $12.0M | $40.8M | 2021 |
John Drewry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Drewry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PAUL CONLEY | 2 | 17 |
| Lily Li | 1 | 2 |
| Landon Merrill | 1 | 1 |
| Gudrun Stengel | 1 | 1 |
| Devon Cayer | 1 | 1 |
| Andrew MacConnell | 1 | 1 |
| Dan Faro | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.